-
CSBIO | On the project, focus on innovation and promote the realization of high-quality development of enterprises
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. was established in September 2000 and listed on the Shenzhen Growth Enterprise Market on August 19, 2011. It is a leading enterprise of heparin series drugs in China and has more than 1,300 employees. In recent years, the company has actively r...Read more -
Innovation leads development CSBIO: Net profit increased by 20.13% in the first half of the year
On August 27, the performance of Changshan Pharmaceutical’s 2021 mid-year report showed that in the first half of this year, the company achieved operating income of 1.417 billion yuan, an increase of 40.36% over the same period of the previous year; net profit attributable to shareholders ...Read more -
Chinese Physician’s Day
To build a dream together in the centennial birthday The doctor is responsible for practicing the original intention August 19, 2021 It’s the fourth Chinese doctor’s day Changshan Pharmaceutical provides all “Respect for life, save the dying and heal the wounded Willing to give ...Read more -
Recognize thrombus
Arteriovenous Thromboembolism Divided into Venous thromboembolism and Arterial Thromboembolism Venous thromboembolism includ Pulmonary embolism and Deep vein thrombosis. Arterial Thromboembolism includ Stroke and heart attack. Venous thromboembolism Contains the following two situations : Pulmona...Read more -
Introduction to the new drug-ibenatide
Hebei Changshan Pharmaceutical Co., Ltd. and ConjuChem LLC of the United States signed a joint venture agreement. The two parties jointly established a Sino-foreign joint venture —Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. With the increasing enr...Read more -
2021 US NCCN guidelines recommend: low molecular weight heparin is the first choice for VTE prevention in hospitalized tumor patients
Malignant tumors are the most important risk factor for venous thrombosis (VTE), and VTE has become the second leading cause of death for tumor patients. Studies have shown that the risk of VTE in cancer patients is at least 4 to 6 times higher than that in non-tumor patients, and VTE increases t...Read more -
[Recruitment of newly-onset type 2 diabetes patients] Recruitment of clinical trial information sharing of newly-onset type 2 diabetes patients Background Information
This study is a randomized, double-blind phase III clinical trial of CJC 1134 PC injection versus placebo initiated by Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. It is planned to enroll 450 patients with type 2 diabetes who have not received diabetes medicat...Read more -
CSBIO Fight the epidemic while speeding up production
The “Recommendations for the Prevention and Treatment of Venous Thromboembolism Related to Novel Coronavirus Pneumonia” pointed out: Nearly 20% of patients with new coronary disease will have coagulation abnormalities, and almost all severe and critical patients have coagulation disor...Read more -
Two misunderstandings of heparin-induced thrombocytopenia
Changshan Medical News Heparin-induced thrombocytopenia (HIT) is a complication characterized by thrombocytopenia caused by heparin, which mainly manifests as thrombocytopenia, platelet activation or thrombosis. There are two clinical types, one is with thrombosis, and the other is only antibody ...Read more -
Are Thrombotic superficial phlebitis（STP）Also a kind of venous thrombosis?
Superficial thrombophlebitis (STP), also known as superficial vein thrombosis, is an inflammatory reaction in the lumen of the superficial vein, accompanied by thrombosis. Epidemiological data show that the incidence of STP is about 3% to 11% [1]. The disease is more common in women. The ratio of...Read more -
Anticoagulant effect of low molecular weight heparin on new coronary pneumonia
1.Diagnosis and Treatment for COVID-19 (Trial version 8) by National Health Commission of the P.R.C. The risk of thromboembolism is higher in severe or critical patients,……, Anticoagulants should be used prophylactically. In case of thromboembolism, anticoagulant therapy should be car...Read more -
Announcement that the Hebei Changshan’s bovine source heparin products have obtained Halal certification
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) bovine source heparin sodium raw materials and heparin sodium injection passed the Shandong Halal Certification Service Co., Ltd. (SHC) on-site audit according to MUI HAS23000 and MS1500:20...Read more
